Literature DB >> 23898

Psychotropic drugs as potential antitumor agents: a selective screening study.

J S Driscoll, N R Melnick, F R Quinn, N Lomax, J P Davignon, R Ing, B J Abott, G Congleton, L Dudeck.   

Abstract

Compounds with known psychotropic properties were tested for activity in murine ip L1210 leukemia and B 16 melanoma in a protocol designed to obtain leads for new antitumor agents which might also possess central nervous system (CNS) antitumor properties. Barbiturates and hallucinogenic compounds were the only compound types deliberately excluded. Representatives from most of the other known CNS agent classes were included among the 297 psychotropic drugs evaluated. Sixteen of these agents were reproducibly active against the L1210 tumor system with T/C values of 125%. Phenothiazines such as fluphenazine and butyrophenones such as triperidol were prominent among the confirmed active structural types. Dopamine, a beta-phenethylamine neurotrasmitter, was active. While reproducible B16 melanoma activity was not observed among the psychotropic drugs, most of the L1210 confirmed active agents were effective against the ip P388 tumor model and also were active in vitro against KB cells. Ic L1210 activity was not observed among the few compounds chosen for testing in that tumor system. The yield of ip L1210 confirmed actives from this group of psychotropic agents was 18 times that which would have been expected from the random screening of compounds.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 23898

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

1.  Non-synonymous variants in the AMACR gene are associated with schizophrenia.

Authors:  Irina N Bespalova; Martina Durner; Benjamin P Ritter; Gary W Angelo; Enrique Rossy-Fullana; Jose Carrion-Baralt; James Schmeidler; Jeremy M Silverman
Journal:  Schizophr Res       Date:  2010-09-26       Impact factor: 4.939

2.  The incidence of cancer in schizophrenic patients.

Authors:  P B Mortensen
Journal:  J Epidemiol Community Health       Date:  1989-03       Impact factor: 3.710

3.  Natural killer cell function in adolescent and adult schizophrenic patients.

Authors:  Franz Resch; G Paul Amminger; Harald Aschauer; Christian Müller; Christoph Zielinski
Journal:  Eur Child Adolesc Psychiatry       Date:  1993-07       Impact factor: 4.785

Review 4.  Cancer and the Dopamine D2 Receptor: A Pharmacological Perspective.

Authors:  Jillian S Weissenrieder; Jeffrey D Neighbors; Richard B Mailman; Raymond J Hohl
Journal:  J Pharmacol Exp Ther       Date:  2019-04-18       Impact factor: 4.030

Review 5.  Merbarone: an antitumor agent entering clinical trials.

Authors:  A Glover; H G Chun; L M Kleinman; D A Cooney; J Plowman; C K Grieshaber; L Malspeis; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

6.  Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.

Authors:  M Slavik; P Y Liu; E H Kraut; R B Natale; L E Flaherty; V K Sondak
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

7.  Schizophrenia, cancer and obstetric complications in an evolutionary perspective-an empirically based hypothesis.

Authors:  Antonio Preti; Daniel R Wilson
Journal:  Psychiatry Investig       Date:  2010-12-15       Impact factor: 2.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.